ANSPOR Drug Patent Profile
✉ Email this page to a colleague
When do Anspor patents expire, and when can generic versions of Anspor launch?
Anspor is a drug marketed by Glaxosmithkline and is included in two NDAs.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Summary for ANSPOR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 74 |
Patent Applications: | 4,762 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANSPOR at DailyMed |
US Patents and Regulatory Information for ANSPOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ANSPOR | cephradine | CAPSULE;ORAL | 061859-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | ANSPOR | cephradine | FOR SUSPENSION;ORAL | 061866-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline | ANSPOR | cephradine | CAPSULE;ORAL | 061859-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |